【摘要】 目的　评价血管内支架在门静脉主干良性狭窄导致的门静脉高压中的应用价值。方法　 6例门静脉良性狭窄患者 (其中炎症性狭窄 3例 ,肝硬化肝移植术后 3例 )实施了门静脉支架置入术 ,观察术后门静脉压力变化、支架通畅、临床症状、并发症及患者存活情况。结果　 6例患者均成功置入门静脉支架 (共 6枚 ) ,门静脉压力由术前的 (37 3± 4 7)cmH2 O(1cmH2 O =0 0 98kPa)降至术后的 (18 0± 1 9)cmH2 O (P <0 0 0 1) ,患者门静脉高压症状完全缓解 ,无手术相关的严重并发症。平均随诊 2 6个月 (5～ 36个月 ) ,所有患者门静脉保持通畅 ,除 1例患者死于肝移植后其他并发症外 ,其他患者均存活。结论　门静脉支架置入治疗门静脉主干良性狭窄引起的门静脉高压是安全及有效的更多还原

【Abstract】 Objective To evaluate the value of endovascular stent in the treatment of portal hypertension caused by benign main portal vein stenosis.Methods Portal vein stents were implanted in （6 patients） with benign main portal vein stenosis （inflammatory stenosis in 3 cases,postprocedure of liver transplantation in another 3 cases）.The change of portal vein pressure,the patency of portal vein,relative clinical symptoms,complications,and survival were evaluated.Results Six metallic stents were successfully placed across the portal vein stenotic or obstructive lesions in all 6 patients.Mean portal venous pressure decreased significantly after stent implantation from （37.3±4.7） cm H₂O （1 cm H₂O=0.098 kPa）to （18.0±1.9） cm H₂O （P<0.001）.The portal blood flow was restored,and the symptoms caused by portal hypertension were eliminated.There was no severe procedure-related complication.Follow-up time was from （5 to） 36 months.The portal vein remained patent during the follow-up.All patients survived except one patient who died of other complications of liver transplantation.Conclusion Percutaneous portal vein stent placement for the treatment of the benign main portal vein stenosis is safe and effective.更多还原